Article Details
Retrieved on: 2024-12-24 18:50:24
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Indapta Therapeutics' funding from various investors, including venture philanthropy, to develop NK cell therapies. It links philanthropy with cancer immunotherapy targeting CD20/CD38 and autoimmune diseases, reinforcing therapeutic innovation.
Article found on: pulse2.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here